

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G/A
(Amendment No. 2)

Under the Securities Exchange Act of 1934

Collectar Biosciences, Inc.
(Name of Issuer)

Common Shares
(Title of Class of Securities)

15117F500
(CUSIP Number)

October 25, 2022
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

NYC#: 139632.2

CUSIP No. **15117F500**

13G/A

Page 2 of 9 Pages

1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
	Rosalind Advisors, Inc.
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
	(a) <input type="checkbox"/>
	(b) <input type="checkbox"/>
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION
	ONTARIO, CANADA
	5. SOLE VOTING POWER
	0
	6. SHARED VOTING POWER
	605,228 shares of Common Stock
	2,158,272 shares of Common Stock issuable upon exercise of warrants
	7. SOLE DISPOSITIVE POWER
	0
	8. SHARED DISPOSITIVE POWER
	605,228 shares of Common Stock
	2,158,272 shares of Common Stock issuable upon exercise of warrants
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	605,228 shares of Common Stock
	2,158,272 shares of Common Stock issuable upon exercise of warrants
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) <input type="checkbox"/>
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	9.9% ¹
12.	TYPE OF REPORTING PERSON (see instructions)
	CO

¹ This percentage is calculated based upon 9,385,272 shares of the Issuer's common stock outstanding as of October 24, 2022 in accordance with Issuer's prospectus supplement filed on October 24, 2022. However, as more fully described in Item 3, the securities reported in rows (8), (10) and (11) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (8), (10) and (11).

NYC#: 139632.2

NYC#: 139632.2

CUSIP No. **15117F500**

13G/A

Page 3 of 9 Pages

1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
	Steven Salamon
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/>
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION ONTARIO, CANADA
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5. SOLE VOTING POWER 0
	6. SHARED VOTING POWER 605,228 shares of Common Stock 2,158,272 shares of Common Stock issuable upon exercise of warrants
	7. SOLE DISPOSITIVE POWER 0
	8. SHARED DISPOSITIVE POWER 605,228 shares of Common Stock 2,158,272 Shares of Common Stock issuable upon exercise of warrants
	9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 605,228 shares of Common Stock 2,158,272 shares of Common Stock issuable upon exercise of warrants
	10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) <input type="checkbox"/>
	11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.9%
	12. TYPE OF REPORTING PERSON (see instructions) IN

NYC#: 139632.2

CUSIP No. **15117F500**

13G/A

Page 4 of 9 Pages

1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
	Gilad Aharon
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/>

3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION
	ONTARIO, CANADA
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5. SOLE VOTING POWER
	0
	6. SHARED VOTING POWER
	605,228 shares of Common Stock 2,158,272 shares of Common Stock issuable upon exercise of warrants
	7. SOLE DISPOSITIVE POWER
	3,900 shares of Common Stock
	8. SHARED DISPOSITIVE POWER
	605,228 shares of Common Stock 2,158,272 Shares of Common Stock issuable upon exercise of warrants
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	605,228 shares of Common Stock 2,158,272 shares of Common Stock issuable upon exercise of warrants
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) <input type="checkbox"/>
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	9.97% ¹
12.	TYPE OF REPORTING PERSON (see instructions)
	IN

NYC#: 139632.2

CUSIP No. **15117F500**

13G/A

Page 5 of 9 Pages

1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
	Rosalind Master Fund L.P.
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
	(a) <input type="checkbox"/> (b) <input type="checkbox"/>
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION
	CAYMAN ISLANDS
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5. SOLE VOTING POWER
	0
	6. SHARED VOTING POWER
	605,228 shares of Common Stock 2,158,272 shares of Common Stock issuable upon exercise of warrants
	7. SOLE DISPOSITIVE POWER
	0
	8. SHARED DISPOSITIVE POWER
	605,228 shares of Common Stock 2,158,272 shares of Common Stock issuable upon exercise of warrants
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	605,228 shares of Common Stock 2,158,272 shares of Common Stock issuable upon exercise of warrants
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) <input type="checkbox"/>

11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	9.9% ¹
12.	TYPE OF REPORTING PERSON (see instructions)
	PN

NYC#: 139632.2

CUSIP No. **15117F500**

13G/A

Page 6 of 9 Pages

Item 1.

- (a) Name of Issuer: CELLECTAR BIOSCIENCES, INC.
- (b) Address of Issuer's Principal Executive Offices
100 Campus Drive, Florham Park, New Jersey 07932

Item 2.

- (a) Name of Person Filing
Rosalind Advisors, Inc. ("Advisor" to RMF)
Rosalind Master Fund L.P. ("RMF")
Steven Salamon ("President")
Steven Salamon is the portfolio manager of the Advisor which advises RMF.
Gilad Aharon is the portfolio manager and member of the Advisor which advises RMF.
- (b) Address of the Principal Office or, if none, residence
Rosalind Advisors, Inc.
175 Bloor Street East
Suite 1316, North Tower
Toronto, Ontario
M4W 3R8 Canada

Rosalind Master Fund L.P.
P.O. Box 309
Ugland House, Grand Cayman
KY1-1104, Cayman Islands

Steven Salamon
175 Bloor Street East
Suite 1316, North Tower
Toronto, Ontario
M4W 3R8 Canada

Gilad Aharon
175 Bloor Street East
Suite 1316, North Tower
Toronto, Ontario
M4W 3R8 Canada
- (c) The principal business of Rosalind Advisors, Inc. is to operate as an investment advisory firm and to make public equity investments. The principal occupation of Mr. Salamon is serving as the Portfolio Manager and President of Rosalind Advisors, Inc., which advises Rosalind Master Fund L.P.
- (d) No Reporting Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
- (e) No Reporting Person has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
- (f) Mr. Salamon and Mr. Aharon are citizens of Canada, resident in Ontario

NYC#: 139632.2

CUSIP No. **15117F500**

13G/A

Page 7 of 9 Pages

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

- (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned:

The information as of the date of the event which requires filing of this statement required by Items 5(a) – (c) is set forth in Rows 7 – 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 13 of the cover page for each Reporting Person is based upon the shares reported outstanding in the Issuer’s prospectus supplement filed on October 24, 2022, including the Hybrid Common Warrant shares (“Warrants”) issued to Rosalind Master Fund L.P. Therefore, as of October 24, 2022, the Reporting Persons may be deemed to beneficially own an aggregate of 937,588 shares of Common Stock, representing the 605,228 shares of Common Stock presently owned combined with number of shares of Common Stock that may be acquired by Rosalind Master Fund as of October 24, 2022 under the Warrants without exceeding the 9.9% beneficial ownership limitation on the exercise of the Warrants.

Rosalind Advisors, Inc. is the investment advisor to RMF and may be deemed to be the beneficial owner of shares held by RMF. Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares held by RMF. Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of the shares.

Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1). **Item 5. Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

NYC#: 139632.2

CUSIP No. 15117F500

13G/A

Page 8 of 9 Pages

Instruction. Dissolution of a group requires a response to this item.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Item 7 – 9. Not Applicable

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

11/2/2022
Date

Signature

Steven Salamon/President Rosalind Advisors, Inc.
Name/Title

Exhibit A Joint Filing Agreement

The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of Collectar Biosciences, Inc. is filed jointly, on behalf of each of them.

Rosalind Advisors, Inc.

By: _____

Name: Steven Salamon

Title: President

Rosalind Master Fund L.P.

By: _____

Name: Mike McDonald

Title: Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)

By: _____

Name: Steven Salamon

NYC#: 139632.2

Exhibit A
Joint Filing Agreement

The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of Delcath Systems, Inc. is filed jointly, on behalf of each of them.

Rosalind Advisors, Inc.

By: _____
Name: Steven Salamon
Title: President

Rosalind Master Fund L.P.

By: _____
Name: Mike McDonald
Title: Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)

By: _____
Name: Steven Salamon